sarcosine has been researched along with Autism in 5 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oxytocin is expected as a novel therapeutic agent for autism spectrum disorder (ASD) core symptoms." | 9.41 | Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms. ( Benner, S; Eriguchi, Y; Kameno, Y; Kasai, K; Kato, Y; Kojima, M; Kosaka, H; Kuroda, M; Kuwabara, H; Munesue, T; Murayama, C; Nishimura, T; Okada, T; Ozaki, N; Tsuchiya, K; Yamasue, H; Yassin, W, 2021) |
| "N,N-dimethylglycine, a dietary supplement, has been reported to be beneficial in children with autism and pervasive developmental disorder." | 9.09 | Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. ( Cauller, PL; Dodd, M; Kendall, PR; Kern, JK; Mehta, PJ; Miller, VS, 2001) |
| "Globally, the prevalence of autism is estimated to be less than 1%, especially in high- -income countries." | 6.82 | Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness in Autism Spectrum Disorders. ( Bhardwaj, S; Chopra, C; Dhanjal, DS; Kuca, K; Nepovimova, E; Patocka, J; Plucar, B; Singh, R; Valis, M, 2022) |
| " The major methodologic weaknesses of the study are thought to be the low dosage of DMG and the small sample size." | 6.69 | A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. ( Bolman, WM; Richmond, JA, 1999) |
| "Oxytocin is expected as a novel therapeutic agent for autism spectrum disorder (ASD) core symptoms." | 5.41 | Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms. ( Benner, S; Eriguchi, Y; Kameno, Y; Kasai, K; Kato, Y; Kojima, M; Kosaka, H; Kuroda, M; Kuwabara, H; Munesue, T; Murayama, C; Nishimura, T; Okada, T; Ozaki, N; Tsuchiya, K; Yamasue, H; Yassin, W, 2021) |
| "N,N-dimethylglycine, a dietary supplement, has been reported to be beneficial in children with autism and pervasive developmental disorder." | 5.09 | Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. ( Cauller, PL; Dodd, M; Kendall, PR; Kern, JK; Mehta, PJ; Miller, VS, 2001) |
| "Globally, the prevalence of autism is estimated to be less than 1%, especially in high- -income countries." | 2.82 | Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness in Autism Spectrum Disorders. ( Bhardwaj, S; Chopra, C; Dhanjal, DS; Kuca, K; Nepovimova, E; Patocka, J; Plucar, B; Singh, R; Valis, M, 2022) |
| " The major methodologic weaknesses of the study are thought to be the low dosage of DMG and the small sample size." | 2.69 | A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. ( Bolman, WM; Richmond, JA, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhanjal, DS | 1 |
| Bhardwaj, S | 1 |
| Chopra, C | 1 |
| Singh, R | 1 |
| Patocka, J | 1 |
| Plucar, B | 1 |
| Nepovimova, E | 1 |
| Valis, M | 1 |
| Kuca, K | 1 |
| Kato, Y | 1 |
| Kuwabara, H | 1 |
| Okada, T | 1 |
| Munesue, T | 1 |
| Benner, S | 1 |
| Kuroda, M | 1 |
| Kojima, M | 1 |
| Yassin, W | 1 |
| Eriguchi, Y | 1 |
| Kameno, Y | 1 |
| Murayama, C | 1 |
| Nishimura, T | 1 |
| Tsuchiya, K | 1 |
| Kasai, K | 1 |
| Ozaki, N | 1 |
| Kosaka, H | 1 |
| Yamasue, H | 1 |
| Xia, RR | 1 |
| Bolman, WM | 1 |
| Richmond, JA | 1 |
| Kern, JK | 1 |
| Miller, VS | 1 |
| Cauller, PL | 1 |
| Kendall, PR | 1 |
| Mehta, PJ | 1 |
| Dodd, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Galantamine Versus Placebo in Childhood Autism[NCT00252603] | Phase 3 | 20 participants | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sarcosine and Autism
| Article | Year |
|---|---|
Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness in Autism Spectrum Disorders.
Topics: Autism Spectrum Disorder; Autistic Disorder; Child; Humans; Nutrients; Sarcosine | 2022 |
3 trials available for sarcosine and Autism
| Article | Year |
|---|---|
Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms.
Topics: Administration, Intranasal; Adolescent; Adult; Autistic Disorder; Double-Blind Method; Facial Expres | 2021 |
A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder.
Topics: Adolescent; Adult; Autistic Disorder; Child; Child, Preschool; Cross-Over Studies; Dose-Response Rel | 1999 |
Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder.
Topics: Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Preschool; Double-Blind Met | 2001 |
1 other study available for sarcosine and Autism
| Article | Year |
|---|---|
Effectiveness of nutritional supplements for reducing symptoms in autism-spectrum disorder: a case report.
Topics: Autistic Disorder; Child; Child Behavior; Communication; Dietary Supplements; Humans; Interpersonal | 2011 |